Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.

Thrombosis research - 1 Jan 2007

Yin Tong, Miyata Toshiyuki

Abstract excerpt

Warfarin is the most widely prescribed oral anticoagulant, but there is greater than 10-fold interindividual variability in the dose required to attain a therapeutic response. Information from pharmacogenomics, the study of the interaction of an individual's genotype and drug response, can help optimize drug efficacy while minimizing adverse drug reactions. Pharmacogenetic analysis of two genes, the warfarin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Mixed Function Oxygenases

Share to Pharmacogenetics

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 17161452
DOI: 10.1016/j.thromres.2006.10.021

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.PMID 17161452Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Pharmacogenetics of warfarin.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.Semantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

Warfarin pharmacogenomics.Semantic proximity Read ↗

Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.Semantic proximity Read ↗

Pharmacogenomics of anticoagulants: steps toward personal dosageSemantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

Pharmacogenetics in warfarin therapySemantic proximity Read ↗

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.Semantic proximity Read ↗

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.